Acalabrutinib (BioDeep_00000795727)
代谢物信息卡片
Acalabrutinib
化学式: C26H23N7O2 (465.1913138)
中文名称: 阿卡拉布替尼(ACP-196)
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
InChI: InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D000970 - Antineoplastic Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:167707
- KEGGdrug: D10893
- PubChem: 71226662
- DrugBank: DB11703
- ChEMBL: CHEMBL3707348
- CAS: 1639823-20-3
- CAS: 1420477-60-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Buyun Chen, Diansong Zhou, Hua Wei, Marmor Yotvat, Li Zhou, Jean Cheung, Nicole Sarvaria, Richard Lai, Shringi Sharma, Karthick Vishwanathan, Joseph Ware. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
British journal of clinical pharmacology.
2022 Aug; 88(8):3716-3729. doi:
10.1111/bcp.15278. [PMID: 35165925] - Yan Xu, Raquel Izumi, Helen Nguyen, Anna Kwan, Howard Kuo, Jeannine Madere, J Greg Slatter, Terry Podoll, Karthick Vishwanathan, Thomas Marbury, William Smith, Richard A Preston, Shringi Sharma, Joseph A Ware. Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
Journal of clinical pharmacology.
2022 06; 62(6):812-822. doi:
10.1002/jcph.2013. [PMID: 34897701] - Jonathan J Pinney, Sara K Blick-Nitko, Andrea M Baran, Derick R Peterson, Hannah E Whitehead, Raquel Izumi, Veerendra Munugalavadla, Karl R Van DerMeid, Paul M Barr, Clive S Zent, Michael R Elliott, Charles C Chu. The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.
Haematologica.
2022 06; 107(6):1460-1465. doi:
10.3324/haematol.2021.279560. [PMID: 35172559] - Chunhua Ma, Qingyun Li, Minghao Zhao, Goujie Fan, Jie Zhao, Dandan Zhang, Shouning Yang, Shuting Zhang, Dingding Gao, Longfei Mao, Liang Zhu, Wei Li, Guiqing Xu, Yuqin Jiang, Qingjie Ding. Discovery of 1-Amino-1H-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.
Journal of medicinal chemistry.
2021 11; 64(21):16242-16270. doi:
10.1021/acs.jmedchem.1c01559. [PMID: 34672559] - H Yesid Estupiñán, Qing Wang, Anna Berglöf, Gerard C P Schaafsma, Yuye Shi, Litao Zhou, Dara K Mohammad, Liang Yu, Mauno Vihinen, Rula Zain, C I Edvard Smith. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Leukemia.
2021 05; 35(5):1317-1329. doi:
10.1038/s41375-021-01123-6. [PMID: 33526860] - Miran Rada, Zahraa Qusairy, Marta Massip-Salcedo, Salvador Macip. Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
Molecular cancer research : MCR.
2021 04; 19(4):549-554. doi:
10.1158/1541-7786.mcr-20-0814. [PMID: 33328281] - Brooke Benner, William E Carson. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
Journal of hematology & oncology.
2021 01; 14(1):15. doi:
10.1186/s13045-020-00999-8. [PMID: 33441177] - Zheli Jiang, Lu Shi, Yu Zhang, Guanyang Lin, Yingying Wang. Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2020 Nov; 191(?):113613. doi:
10.1016/j.jpba.2020.113613. [PMID: 32971496] - Mohamed E Shaker, Hesham A M Gomaa, Khalid S Alharbi, Mohammad M Al-Sanea, Mohamed E El-Mesery, Sara H Hazem. Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide/galactosamine-induced hepatic damage.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2020 Nov; 131(?):110736. doi:
10.1016/j.biopha.2020.110736. [PMID: 33152913] - Tom Wilkinson, Rupert Dixon, Clive Page, Miles Carroll, Gareth Griffiths, Ling-Pei Ho, Anthony De Soyza, Timothy Felton, Keir E Lewis, Karen Phekoo, James D Chalmers, Anthony Gordon, Lorcan McGarvey, Jillian Doherty, Robert C Read, Manu Shankar-Hari, Nuria Martinez-Alier, Michael O'Kelly, Graeme Duncan, Roelize Walles, James Sykes, Charlotte Summers, Dave Singh. ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial.
Trials.
2020 Jul; 21(1):691. doi:
10.1186/s13063-020-04584-9. [PMID: 32736596] - Elise A Chong, Lindsey E Roeker, Mazyar Shadman, Matthew S Davids, Stephen J Schuster, Anthony R Mato. BTK Inhibitors in Cancer Patients with COVID-19: 'The Winner Will be the One Who Controls That Chaos' (Napoleon Bonaparte).
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 07; 26(14):3514-3516. doi:
10.1158/1078-0432.ccr-20-1427. [PMID: 32345646] - Santiago Thibaud, Douglas Tremblay, Sheena Bhalla, Brittney Zimmerman, Keith Sigel, Janice Gabrilove. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
British journal of haematology.
2020 07; 190(2):e73-e76. doi:
10.1111/bjh.16863. [PMID: 32433778] - Mark Roschewski, Michail S Lionakis, Jeff P Sharman, Joseph Roswarski, Andre Goy, M Andrew Monticelli, Michael Roshon, Stephen H Wrzesinski, Jigar V Desai, Marissa A Zarakas, Jacob Collen, Keith Rose, Ahmed Hamdy, Raquel Izumi, George W Wright, Kevin K Chung, Jose Baselga, Louis M Staudt, Wyndham H Wilson. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
Science immunology.
2020 06; 5(48):. doi:
10.1126/sciimmunol.abd0110. [PMID: 32503877] - Caroline E O'Riordan, Gareth S D Purvis, Debora Collotta, Nadine Krieg, Bianka Wissuwa, Madeeha H Sheikh, Gustavo Ferreira Alves, Shireen Mohammad, Lauren A Callender, Sina M Coldewey, Massimo Collino, David R Greaves, Christoph Thiemermann. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
Frontiers in immunology.
2020; 11(?):581758. doi:
10.3389/fimmu.2020.581758. [PMID: 33162995] - Jennifer Series, Cédric Garcia, Marie Levade, Julien Viaud, Pierre Sié, Loïc Ysebaert, Bernard Payrastre. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Haematologica.
2019 11; 104(11):2292-2299. doi:
10.3324/haematol.2018.207183. [PMID: 30819914] - Ali S Abdelhameed, Amer M Alanazi, Ahmed H Bakheit, Eman S Hassan, Rashed N Herqash, Fahad M Almutairi. Novel BTK inhibitor acalabrutinib (ACP-196) tightly binds to site I of the human serum albumin as observed by spectroscopic and computational studies.
International journal of biological macromolecules.
2019 Apr; 127(?):536-543. doi:
10.1016/j.ijbiomac.2019.01.083. [PMID: 30664965] - Viola Denzinger, Kristina Busygina, Janina Jamasbi, Isabell Pekrul, Michael Spannagl, Christian Weber, Reinhard Lorenz, Wolfgang Siess. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Thrombosis and haemostasis.
2019 Mar; 119(3):397-406. doi:
10.1055/s-0039-1677744. [PMID: 30685871] - Shruti Surendran, David Paul, Sunil Pokharkar, Sagar Choulwar, Abhijeet Deshpande, Sanjeev Giri, N Satheeshkumar. Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.
Journal of pharmaceutical and biomedical analysis.
2019 Feb; 164(?):509-513. doi:
10.1016/j.jpba.2018.11.012. [PMID: 30453157] - Terry Podoll, Paul G Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi, J Greg Slatter. Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.
Drug metabolism and disposition: the biological fate of chemicals.
2019 02; 47(2):145-154. doi:
10.1124/dmd.118.084459. [PMID: 30442651] - Caroline E O'Riordan, Gareth S D Purvis, Debora Collotta, Fausto Chiazza, Bianka Wissuwa, Sura Al Zoubi, Lara Stiehler, Lukas Martin, Sina M Coldewey, Massimo Collino, Christoph Thiemermann. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
Frontiers in immunology.
2019; 10(?):2129. doi:
10.3389/fimmu.2019.02129. [PMID: 31552054] - V K Patel, B Lamothe, M L Ayres, J Gay, J P Cheung, K Balakrishnan, C Ivan, J Morse, M Nelson, M J Keating, W G Wierda, J R Marszalek, V Gandhi. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Leukemia.
2018 04; 32(4):920-930. doi:
10.1038/leu.2017.321. [PMID: 29099493] - James J Crawford, Adam R Johnson, Dinah L Misner, Lisa D Belmont, Georgette Castanedo, Regina Choy, Melis Coraggio, Liming Dong, Charles Eigenbrot, Rebecca Erickson, Nico Ghilardi, Jonathan Hau, Arna Katewa, Pawan Bir Kohli, Wendy Lee, Joseph W Lubach, Brent S McKenzie, Daniel F Ortwine, Leah Schutt, Suzanne Tay, BinQing Wei, Karin Reif, Lichuan Liu, Harvey Wong, Wendy B Young. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
Journal of medicinal chemistry.
2018 03; 61(6):2227-2245. doi:
10.1021/acs.jmedchem.7b01712. [PMID: 29457982] - Sara Roman-Garcia, Sara V Merino-Cortes, Sofia R Gardeta, Marjolein J W de Bruijn, Rudi W Hendriks, Yolanda R Carrasco. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
Frontiers in immunology.
2018; 9(?):2027. doi:
10.3389/fimmu.2018.02027. [PMID: 30237801]